K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Clinical trials sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, explained in plain language.
A subsidiary of Zentalis Pharmaceuticals, a biopharmaceutical company developing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for drug-resistant ovarian cancer: experimental pill targets tumor weakness Results expected Dec 2026 (estimated) May already have reported ↗
-
Experimental drug combo targets tough bone cancer
Disease control CompletedThis early-stage trial tested a new drug called azenosertib (ZN-c3) combined with the chemotherapy gemcitabine in 31 people aged 12 and older with osteosarcoma that had relapsed or stopped responding to treatment. The goal was to see if the combination is safe and whether it can …
Phase 1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control CompletedThis study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…
Phase 1/2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase 1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for women with Hard-to-Treat uterine cancer?
Disease control CompletedThis study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…
Phase 2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC